DGAP-Adhoc: aap Implantate AG: Private Equity partner acquires 67% of aap's subsidiary for Orthopaedic products for the Asian market

aap Implantate AG / Key word(s): Joint Venture/Contract

28.06.2013 12:32

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

aap Implantate AG (XETRA: AAQ.DE) and a British Virgin Island-based Private
Equity Company ('PE Company') announced today that they have entered a
joint venture for aap's reconstructive implant business in the greater
Asian market. Under the terms of the agreement, the PE Company will acquire
67% of the shares of aap's reconstructive implant subsidiary, aap Joints
GmbH, for a consideration of EUR 3 million in cash, subject to adjustments
for working capital. The notary authorization of all agreements is
scheduled July 3rd.

aap Joints GmbH focuses on reconstructive implants (hips, knees, shoulder)
and related products, including the bone cement brand C-ment(R). In 2012
aap Joints GmbH recorded sales of EUR 2.2 million. Outside of the greater
Asian market, aap Joints GmbH will continue to serve its existing customer
base in Europe and the Middle East.

aap Implantate AG will update its guidance for the third quarter and the
full year 2013 to include the impact of the joint venture in conjunction
with the publication of the report for the second quarter on August 14,
2013.

This release contains forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. Many factors could cause the actual results, performance or
achievements of aap to be materially different from those that may be
expressed or implied by such statements. These factors include those
discussed in aap's public reports. Forward-looking statements therefore
speak only as of the date they are made. aap does not assume any obligation
to update the forward-looking statements contained in this release or to
conform them to future events or developments.
____
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -

aap is a global medical device company headquartered in Berlin, Germany
that develops, manufactures and markets innovative biomaterials and
implants that are used in orthopedic procedures. The Company's products,
which include a full line of plating systems, cannulated screws and bone
cement products, are primarily used in the orthopedic specialty areas of
trauma and spine repair. The Company's products are sold through its direct
sales force, distribution partners and license agreements with OEM
partners. aap's stock is listed in the Prime Standard segment of the
Frankfurt Stock Exchange. For more information, please visit www.aap.de, or
download the Company's investor relations app from the Apple's App Store or
Google Play.

For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099
Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich@aap.de

---------------------------------------------------------------------------

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------